Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-11-28FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for the irbesartan and hydrochlorothiazide combination from Unichem Pharmaceuticals (USA), Inc. …
-
FDA approval · 2025-11-25FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for a generic irbesartan and hydrochlorothiazide fixed-dose combination tablet manufactured by M…
-
FDA approval · 2025-11-25FDA Approved: IRBESARTAN — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for irbesartan filed by NorthStar RxLLC under ANDA 202254, authorizing changes to the product's appr…
-
FDA approval · 2025-11-24FDA Approved: OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE — Original Application (Micro Labs Limited)
The FDA approved a fixed-dose combination tablet containing olmesartan medoxomil, amlodipine besilate, and hydrochlorothiazide under Micro L…
-
EMA approval · 2025-11-19EMA Authorised: Dafiro (amlodipine;valsartan) — Novartis Europharm Limited
The EMA authorised Dafiro, a fixed-dose combination of amlodipine and valsartan, for the treatment of hypertension, with Novartis Europharm …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-19EMA Authorised: Copalia (valsartan;amlodipine (as amlodipine besilate)) — Novartis Europharm Limited
The European Medicines Agency authorised Copalia, a fixed-dose combination of valsartan and amlodipine, for hypertension.
-
EMA approval · 2025-11-19EMA Authorised: Exforge (valsartan;amlodipine (as amlodipine besilate)) — Novartis Europharm Limited
The EMA authorised Exforge, a fixed-dose combination of valsartan and amlodipine, for hypertension; the marketing authorization holder is No…
-
FDA approval · 2025-11-14FDA Approved: ALDACTONE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for Aldactone (spironolactone) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2025-11-14FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for Spironolactone and Hydrochlorothiazide, a combination diuretic. This re…
-
FDA approval · 2025-11-14FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves the original application for diltiazem hydrochloride (Alembic Pharmaceuticals Limited), a generic product, for use in treating …
-
FDA approval · 2025-11-12FDA Approved: IRBESARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for IRBESARTAN (irbesartan) from Aurobindo Pharma Limited. This action approves changes under the AN…
-
FDA approval · 2025-11-04FDA Approved: IRBESARTAN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original generic application for irbesartan (IRBESARTAN) by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2025-10-29FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for a Losartan Potassium product from Granules Pharmaceuticals Inc., enabling a generic losartan…
-
FDA approval · 2025-10-28FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Sagent Pharmaceuticals)
FDA approved the original application for Nicardipine hydrochloride from Sagent Pharmaceuticals (ANDA 219608), establishing a generic produc…
-
FDA approval · 2025-10-24FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Losartan Potassium and Hydrochlorothiazide, a generic combination medicine.…
-
FDA approval · 2025-10-23FDA Approved: JAVADIN — Original Application (Azurity Pharmaceuticals, Inc.)
The FDA approved JAVADIN, an original application for clonidine hydrochloride oral from Azurity Pharmaceuticals, Inc. This adds a clonidine …
-
FDA approval · 2025-10-22FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Caplin Steriles Limited)
FDA approves an original ANDA for Nicardipine Hydrochloride as a generic product by Caplin Steriles Limited.
-
FDA approval · 2025-10-10FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lifestar Pharma LLC)
The FDA approved a supplemental application for a generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide by Lifestar…
-
FDA approval · 2025-10-09FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for a granules formulation of losartan potassium and hydrochlorothiazide from Granules Pharmaceutica…
-
FDA approval · 2025-10-07FDA Approved: LASIX ONYU — Original Application (SQ Innovation, Inc.)
FDA approves LASIX ONYU for the same active ingredient furosemide under an Original Application by SQ Innovation, Inc. The product is now au…
-
FDA approval · 2025-10-02FDA Approved: LABETALOL HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original generic application for labetalol hydrochloride, with Amneal Pharmaceuticals LLC as the sponsor.
-
FDA approval · 2025-09-30FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for NorthStar Rx LLC to market a generic losartan potassium and hydrochlorothiazide combination tabl…
-
FDA approval · 2025-09-30FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide for the treatme…
-
FDA approval · 2025-09-30FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for IRBESARTAN submitted by Camber Pharmaceuticals, Inc.
-
FDA approval · 2025-09-30FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (NorthStar RxLLC)
FDA approved the supplemental application for a generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide for treatment…